Τicagrelor Versus Prasugrel in Diabetic Patients: a Pharmacodynamic Study

Exclusion Criteria

• •Treatment with other investigational agents (including placebo) or devices within 30 days prior to randomization or planned use of investigational agents or devices prior to the Day 30 visit.
• •Pregnancy
• •Breastfeeding
• •Inability to give informed consent or high likelihood of being unavailable for the Day 30 follow up.
• •Cardiogenic shock
• •Major periprocedural complications (death, stent thrombosis, vessel perforation, arrhythmias requiring cardioversion, temporary pacemaker insertion or intravenous antiarrhythmic agents, respiratory failure requiring intubation, vascular injury (pseudoaneurysm, arteriovenous shunt, retroperitoneal bleeding or hematoma \>5 cm at the arterial catheter insertion site), major bleeding (need for bood transfusion or drop in haemoglobin post-PCI by ≥ 5 gr/ dl or intracranial bleeding).
• •Unsuccessful PCI (residual stenosis \> 30% or flow \< ΤΙΜΙ 3) or planned staged PCI in the next 30 days after randomization
• •Requirement for oral anticoagulant prior to the Day 30 visit
• •Current or planned therapy with other thienopyridine class of ADP receptor inhibitors.
• •Known hypersensitivity to prasugrel or ticagrelor
• •History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal bleeding within the previous 6 months.
• •Other bleeding diathesis, or considered by investigator to be at high risk for bleeding on longterm thienopyridine therapy.
• •Any previous history of ischemic stroke, intracranial hemorrhage or disease (neoplasm, arteriovenous malformation, aneurysm).
• •Thrombocytopenia (\< 100.000/μL) at randomization
• •Anaemia (Hct \< 30%) at randomization
• •Polycytaemia (Hct \> 52%) at randomization
• •Periprocedural IIb/IIIa inhibitors administration
• •Severe allergy to contrast agent, unfractionated heparin, enoxaparin or bivalirudin that cannot be adequately premedicated.
• •Recent (\< 6 weeks) major surgery or trauma, including GABG.
• •Subjects receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors that cannot be discontinued for the duration of the study.
• •Concomitant oral or IV therapy with strong CY P3A inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazana vir, grapefruit juice N1 L/d), CYP3A substrates with narrow therapeutic indices (cyclosporine, quinidine), or strong CYP3A inducers (rifampin /rifampicin, phenytoin, carbamazepine).
• •Increased risk of bradycardiac events.
• •Dialysis required.
• •Age ≥ 75 years
• •Weight \< 60 Kg
• •Severe hepatic impairment
• •Severe uncontrolled chronic obstructive pulmonary disease